Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Regeneron Pharmaceuticals
So what: The phase 3 testing showed good results for treating age-related macular degeneration. Patients suffering from this condition will be pleased to hear the treatment requires fewer injections, saving pain and trips to the doctor.
Now what: This definitely gives a boost to Regeneron's prospects, but there is still a ways to go before final approval. The company plans to submit regulatory applications next year, and we may see more losses until its financials turn around. I'll take a wait-and-see approach until there's a better entry point than the highs of today.
Interested in more info on Regeneron Pharmaceuticals? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his Motley Fool CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.